SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

SOLIRIS Resource Library

Critical resources and information to support your practice

Your practice is busy and time demands are often great. The SOLIRIS® Resource Library has been created to meet your PNH clinical information needs, help you stay abreast of research advances in PNH, and assist with patient management.

Because some of the materials available in the SOLIRIS Resource Library will be sent to your office, and to make Library access as easy as possible, you will need to create a personal account.

We encourage you to check back often, using your email address as the login, for updates, new materials, and evolving clinical insights.

This section of the SOLIRIS Resource Library contains essential tools to manage and counsel your patients with PNH. We encourage you to browse through the following downloadable materials.

Registered Users New Users
Enter your email address to access website materials: Sign Up to access website materials
Email:  
 
 







  

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.